Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.
Case Library Membership
Search free — but unlock advanced filters to find every case involving a specific company or clause.
Already a member? Sign in →
Case Library Membership
inc. VAT
inc. VAT · cancel any time
Secure payment via Stripe
Need access for your team?
Company licences available for compliance teams, medical affairs, and training programmes.
Get a team quote →1,930 cases found
A Diabetologia journal ad for Actos claimed “no long-term cardiovascular concerns” without adequately reflecting SPC qualifications and heart failure warnings. The Panel…
Procter & Gamble complained that Servier promoted unbalanced messages implying acid suppressants increased fracture risk and reduced bisphosphonate efficacy. The Panel and…
A GP complained about an unsolicited promotional email for MacroBid sent to his NHS email via an agency. The Panel and Appeal…
Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel found one release misleading on adverse event/risk-benefit balance, but rejected…
A GP complained about large promotional emails sent on Sandoz’s behalf. The Panel found the email was promotional but could not determine…
A Diabetologia ad for Actos claimed no long-term cardiovascular concerns. The Panel found the claim insufficiently qualified versus the SPC and missing…
Servier’s letter, press release and symposium materials implied acid suppressants increased fracture risk and reduced bisphosphonate efficacy. The Panel and Appeal Board…
A GP complained that a Toviaz ad also promoted tolterodine without prescribing information. The Panel ruled a breach for missing obligatory information,…
A pharmacist challenged comparative efficacy and tolerability claims for Versatis versus pregabalin/gabapentin. The Panel found interim data and SPC references did not…
An anaesthetist complained that a Bayer Schering Pharma advert in The Economist promoted a prescription-only MS medicine to the public and raised…
A dermatologist alleged a Ranbaxy letter implied Co-Cyprindiol contained isotretinoin and erythromycin. The Panel found no breach of Clause 7.2, but said…
Two BMJ advertisements for Gaviscon Advance used in-vitro study abstracts but implied in-vivo/clinical oesophageal protection and wider clinical benefit. The Panel ruled…
A GP complained that a Toviaz ad also promoted tolterodine without required prescribing information. The Panel ruled a breach of Clause 4.1,…
A pharmacist challenged claims that Versatis was comparable to pregabalin (and possibly gabapentin) and had fewer side-effects/interactions. The Panel found interim data…
An anaesthetist complained that a corporate-style MS advertisement in The Economist promoted a prescription-only medicine to the public and raised unfounded hopes.…
Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.
